HK1205125A1 - 巨環抑制劑的多晶形 - Google Patents
巨環抑制劑的多晶形Info
- Publication number
- HK1205125A1 HK1205125A1 HK15105950.0A HK15105950A HK1205125A1 HK 1205125 A1 HK1205125 A1 HK 1205125A1 HK 15105950 A HK15105950 A HK 15105950A HK 1205125 A1 HK1205125 A1 HK 1205125A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hcv
- polymorphic forms
- macrocyclic inhibitor
- macrocyclic
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07101563 | 2007-02-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1205125A1 true HK1205125A1 (zh) | 2015-12-11 |
Family
ID=38229348
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10101152.0A HK1137438A1 (zh) | 2007-02-01 | 2010-02-03 | 的巨環抑制劑的多晶形 |
HK15105950.0A HK1205125A1 (zh) | 2007-02-01 | 2015-06-23 | 巨環抑制劑的多晶形 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10101152.0A HK1137438A1 (zh) | 2007-02-01 | 2010-02-03 | 的巨環抑制劑的多晶形 |
Country Status (25)
Country | Link |
---|---|
US (1) | US8143402B2 (zh) |
EP (1) | EP2118098B1 (zh) |
JP (1) | JP5523110B2 (zh) |
KR (1) | KR101580226B1 (zh) |
CN (3) | CN104230918B (zh) |
AR (2) | AR065136A1 (zh) |
AU (1) | AU2008209696B2 (zh) |
BR (1) | BRPI0806945A2 (zh) |
CA (1) | CA2677170C (zh) |
CL (1) | CL2008000321A1 (zh) |
CY (1) | CY1116339T1 (zh) |
DK (1) | DK2118098T3 (zh) |
ES (1) | ES2524784T3 (zh) |
HK (2) | HK1137438A1 (zh) |
HR (1) | HRP20141137T1 (zh) |
IL (1) | IL199215A (zh) |
MX (1) | MX2009008275A (zh) |
NZ (1) | NZ577568A (zh) |
PL (1) | PL2118098T3 (zh) |
PT (1) | PT2118098E (zh) |
RU (1) | RU2533830C2 (zh) |
SI (1) | SI2118098T1 (zh) |
TW (1) | TWI423968B (zh) |
WO (1) | WO2008092954A2 (zh) |
ZA (1) | ZA200905377B (zh) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
RU2536868C2 (ru) * | 2009-02-27 | 2014-12-27 | Орто-Макнейл-Янссен Фармасьютикалз Инк | Аморфная соль макроциклического ингибитора hcv |
TW201040181A (en) | 2009-04-08 | 2010-11-16 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
US9284307B2 (en) | 2009-08-05 | 2016-03-15 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors |
AU2011209051B2 (en) | 2010-01-27 | 2015-01-15 | AB Pharma Ltd. | Polyheterocyclic compounds highly potent as HCV inhibitors |
CN103534256B (zh) | 2010-12-30 | 2016-08-10 | 益安药业 | 大环丙型肝炎丝氨酸蛋白酶抑制剂 |
KR20140003521A (ko) | 2010-12-30 | 2014-01-09 | 이난타 파마슈티칼스, 인코포레이티드 | 페난트리딘 매크로사이클릭 c형 간염 세린 프로테아제 억제제 |
TW201309690A (zh) | 2011-02-10 | 2013-03-01 | Idenix Pharmaceuticals Inc | 巨環絲胺酸蛋白酶抑制劑,其醫藥組合物及其於治療hcv感染之用途 |
WO2012151271A1 (en) * | 2011-05-04 | 2012-11-08 | Merck Sharp & Dohme Corp. | Processes for preparing inhibitors of the hepatitis c virus |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2012171332A1 (zh) | 2011-06-16 | 2012-12-20 | 爱博新药研发(上海)有限公司 | 抑制丙型肝炎病毒的大环状杂环化合物及其制备和应用 |
AU2012307527B2 (en) * | 2011-09-16 | 2017-07-20 | Sanofi | Aniline derivatives,their preparation and their therapeutic application |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
ES2572329B1 (es) | 2011-10-21 | 2017-08-24 | Abbvie Inc. | Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para uso en el tratamientodel vhc |
BR112014005617A2 (pt) | 2011-10-21 | 2017-06-13 | Abbvie Inc | tratamento de combinação (por exemplo, com abt-072 ou abt -333) de daas para uso no tratamento de hcv |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
JP6154474B2 (ja) | 2012-10-19 | 2017-06-28 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP2964664B1 (en) | 2013-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
CN104995189B (zh) * | 2014-01-21 | 2017-03-29 | 杭州普晒医药科技有限公司 | 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途 |
WO2015180253A1 (zh) * | 2014-05-29 | 2015-12-03 | 杭州普晒医药科技有限公司 | 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途 |
CZ2015220A3 (cs) * | 2015-03-27 | 2016-10-05 | Zentiva, K.S. | Amorfní sůl makrocyklického inhibitoru viru hepatitidy C |
WO2016177625A1 (en) | 2015-05-04 | 2016-11-10 | Sandoz Ag | Amorphous simeprevir potassium |
CN105503851B (zh) * | 2015-12-09 | 2017-06-23 | 重庆润生科技有限公司 | 一种烯基噻唑衍生物的制备方法 |
WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007524576A (ja) * | 2003-02-07 | 2007-08-30 | エナンタ ファーマシューティカルズ インコーポレイテッド | 大環状のc型肝炎セリンプロテアーゼ阻害剤 |
MXPA06003455A (es) * | 2003-09-26 | 2006-05-31 | Schering Corp | Inhibidores macrociclicos de la serina proteasa ns3 del virus de la hepatitis c. |
CN102020697B (zh) * | 2003-10-14 | 2014-10-29 | F·霍夫曼-罗须公司 | 作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺 |
DK1713823T3 (da) * | 2004-01-30 | 2010-03-08 | Medivir Ab | HCV NS-3 serinproteaseinhibitorer |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
-
2008
- 2008-02-01 CN CN201410412076.5A patent/CN104230918B/zh not_active Expired - Fee Related
- 2008-02-01 MX MX2009008275A patent/MX2009008275A/es active IP Right Grant
- 2008-02-01 CL CL200800321A patent/CL2008000321A1/es unknown
- 2008-02-01 AR ARP080100427A patent/AR065136A1/es not_active Application Discontinuation
- 2008-02-01 DK DK08708575.9T patent/DK2118098T3/en active
- 2008-02-01 NZ NZ577568A patent/NZ577568A/en not_active IP Right Cessation
- 2008-02-01 EP EP08708575.9A patent/EP2118098B1/en not_active Not-in-force
- 2008-02-01 AU AU2008209696A patent/AU2008209696B2/en not_active Ceased
- 2008-02-01 JP JP2009547702A patent/JP5523110B2/ja not_active Expired - Fee Related
- 2008-02-01 TW TW097103909A patent/TWI423968B/zh not_active IP Right Cessation
- 2008-02-01 WO PCT/EP2008/051268 patent/WO2008092954A2/en active Application Filing
- 2008-02-01 CA CA2677170A patent/CA2677170C/en not_active Expired - Fee Related
- 2008-02-01 PT PT87085759T patent/PT2118098E/pt unknown
- 2008-02-01 CN CNA2008800030601A patent/CN101589040A/zh active Pending
- 2008-02-01 ES ES08708575.9T patent/ES2524784T3/es active Active
- 2008-02-01 BR BRPI0806945-0A2A patent/BRPI0806945A2/pt not_active Application Discontinuation
- 2008-02-01 CN CN201510303203.2A patent/CN105037347B/zh not_active Expired - Fee Related
- 2008-02-01 RU RU2009132660/04A patent/RU2533830C2/ru not_active IP Right Cessation
- 2008-02-01 PL PL08708575T patent/PL2118098T3/pl unknown
- 2008-02-01 SI SI200831337T patent/SI2118098T1/sl unknown
- 2008-02-01 US US12/518,548 patent/US8143402B2/en not_active Expired - Fee Related
- 2008-02-01 KR KR1020097015553A patent/KR101580226B1/ko not_active IP Right Cessation
-
2009
- 2009-06-07 IL IL199215A patent/IL199215A/en active IP Right Grant
- 2009-07-31 ZA ZA200905377A patent/ZA200905377B/xx unknown
-
2010
- 2010-02-03 HK HK10101152.0A patent/HK1137438A1/zh not_active IP Right Cessation
-
2014
- 2014-11-24 HR HRP20141137AT patent/HRP20141137T1/hr unknown
- 2014-12-11 CY CY20141101034T patent/CY1116339T1/el unknown
-
2015
- 2015-06-23 HK HK15105950.0A patent/HK1205125A1/zh unknown
-
2017
- 2017-06-19 AR ARP170101687A patent/AR108819A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1205125A1 (zh) | 巨環抑制劑的多晶形 | |
HK1245264A1 (zh) | 多晶型 | |
HK1217952A1 (zh) | 用於製備 的大環蛋白酶抑制劑的方法和中間體 | |
HK1200440A1 (zh) | 種抑制劑的結晶形式 | |
HK1156624A1 (zh) | 強效 抑制劑 -噻唑基- -喹啉基-氧基衍生物的結晶形式 | |
HRP20170214T1 (hr) | Amorfna sol makrocikličkog inhibitora hcv | |
PT2094708E (pt) | Pirrolopirazina como inibidor da cinase syk | |
HK1164839A1 (zh) | 用於製備 的大環蛋白酶抑制劑的方法及中間體 | |
GB0619888D0 (en) | New polymorphic forms of pregabalin | |
EP1983997A4 (en) | CRYSTALLINE FORMS OF A FARNESYL DIBENZODIAZEPINONE | |
HK1102210A2 (en) | A kind of mending -mouth of pole-charge | |
ZA200903609B (en) | Motilide polymorphs |